ATE130855T1 - Antikörper gegen latente proteine von menschlichen papillomavirus, diagnostische systeme und methoden. - Google Patents

Antikörper gegen latente proteine von menschlichen papillomavirus, diagnostische systeme und methoden.

Info

Publication number
ATE130855T1
ATE130855T1 AT89304874T AT89304874T ATE130855T1 AT E130855 T1 ATE130855 T1 AT E130855T1 AT 89304874 T AT89304874 T AT 89304874T AT 89304874 T AT89304874 T AT 89304874T AT E130855 T1 ATE130855 T1 AT E130855T1
Authority
AT
Austria
Prior art keywords
antibodies
proteins
methods
latented
papilloma virus
Prior art date
Application number
AT89304874T
Other languages
English (en)
Inventor
Joakim Dillner
Richard A Lerner
Richard Smith
D Elliot Parks
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE130855T1 publication Critical patent/ATE130855T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081DNA viruses
    • C07K16/084Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT89304874T 1988-05-16 1989-05-15 Antikörper gegen latente proteine von menschlichen papillomavirus, diagnostische systeme und methoden. ATE130855T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19440788A 1988-05-16 1988-05-16
US07/323,614 US5180806A (en) 1988-05-16 1989-03-13 Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods

Publications (1)

Publication Number Publication Date
ATE130855T1 true ATE130855T1 (de) 1995-12-15

Family

ID=26889974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89304874T ATE130855T1 (de) 1988-05-16 1989-05-15 Antikörper gegen latente proteine von menschlichen papillomavirus, diagnostische systeme und methoden.

Country Status (10)

Country Link
US (3) US5180806A (de)
EP (1) EP0344940B1 (de)
JP (1) JP2918904B2 (de)
AT (1) ATE130855T1 (de)
CA (1) CA1341287C (de)
DE (1) DE68924928T2 (de)
DK (1) DK173264B1 (de)
ES (1) ES2082775T4 (de)
GR (1) GR3018773T3 (de)
PT (1) PT90574B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
DE69223844T2 (de) * 1991-04-24 1998-04-16 Morinaga Milk Industry Co Ltd Antimikrobielles Peptid und antimikrobieller Wirkstoff
PT523391E (pt) * 1991-07-13 2003-08-29 Dade Behring Marburg Gmbh Utilizacao dos peptidos derivados dos genes hpv-16 e6 e e7 para fins de diagnostico
DE4123760C2 (de) * 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
DE19819476C1 (de) * 1998-04-30 2000-01-05 Deutsches Krebsforsch Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
GB2353581B (en) 1999-08-27 2003-06-11 Uponor Ltd Swage lining
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
JP2001172200A (ja) * 1999-12-17 2001-06-26 Meneki Seibutsu Kenkyusho:Kk ヒトナプシンaに対する抗体およびこれを用いる医薬
AU2001251394A1 (en) 2000-04-05 2001-10-23 Impact Diagnostics, Inc. Immunological methodology for discerning human papillomavirus
EP1288292A1 (de) * 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Lange Peptiden die 22-40 Aminosäuren enthalten und die eine immunspezifische Immunantwort induzieren
CA2431500C (en) 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
WO2002050537A1 (en) * 2000-12-21 2002-06-27 Biosignature Diagnostics, Inc. Absorbance multiplex technology
US6933123B2 (en) 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
GB2379220A (en) * 2001-08-13 2003-03-05 Univ York Antibodies to HPV E2 protein
ATE557099T1 (de) * 2003-09-05 2012-05-15 Genencor Int Hpv cd8+ t-zell-epitope
EP1708745B1 (de) * 2003-12-23 2012-04-18 Arbor Vita Corporation Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US8051950B2 (en) * 2006-08-03 2011-11-08 Glacier Bay, Inc. System for reducing acoustic energy
WO2010129821A1 (en) 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8865162B2 (en) * 2008-06-13 2014-10-21 Oncohealth Corp. Monoclonal antibodies against HPV proteins
AU2008269721B2 (en) * 2007-05-31 2013-01-10 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
CA2771863A1 (en) * 2009-08-26 2011-03-17 Selecta Biosciences, Inc. Compositions that induce t cell help
WO2011085231A2 (en) * 2010-01-08 2011-07-14 Selecta Biosciences, Inc. Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines
US9128094B2 (en) 2010-01-08 2015-09-08 Oncohealth Corp. High throughput cell-based HPV immunoassays for diagnosis and screening of HPV-associated cancers
CN103940993A (zh) * 2013-01-23 2014-07-23 艾托金生物医药(苏州)有限公司 用于检测抗人乳头瘤病毒抗体的抗原及试剂盒和应用
MA49512A (fr) * 2017-06-28 2020-05-06 Regeneron Pharma Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
CA3088837A1 (en) * 2018-01-24 2019-08-01 The Council Of The Queensland Institute Of Medical Research Hpv immunotherapy
CN113164445A (zh) 2018-08-02 2021-07-23 得克萨斯系统大学评议会 Tlr1/2激动剂地普罗考姆的佐剂作用协同增效检查点抑制性抗体以消除疾病
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
EP4103283A4 (de) 2020-03-26 2024-02-28 Provectus Pharmatech, Inc. Neue verwendungen von halogenierten xanthenen in der onkologie und virologie
CN112920267B (zh) * 2021-03-09 2021-08-13 北京康乐卫士生物技术股份有限公司 一种抗人乳头瘤病毒31型的单克隆中和抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748109A (en) * 1983-07-01 1988-05-31 Baird Phillip J Assay method and reagent to determine antibodies to papillomavirus virions
LU85462A1 (fr) * 1984-07-11 1986-02-12 Univ Louvain Nouvelles compositions polymeres,procedes pour leur production et leurs applications
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus

Also Published As

Publication number Publication date
DK234789A (da) 1989-11-17
US5180806A (en) 1993-01-19
US5401627A (en) 1995-03-28
EP0344940B1 (de) 1995-11-29
DK173264B1 (da) 2000-05-29
EP0344940A2 (de) 1989-12-06
PT90574A (pt) 1989-11-30
PT90574B (pt) 1994-09-30
CA1341287C (en) 2001-08-28
GR3018773T3 (en) 1996-04-30
JPH0296593A (ja) 1990-04-09
ES2082775T4 (es) 1996-08-01
EP0344940A3 (de) 1991-11-13
DE68924928T2 (de) 1996-10-17
DK234789D0 (da) 1989-05-12
JP2918904B2 (ja) 1999-07-12
ES2082775T3 (es) 1996-04-01
US5486453A (en) 1996-01-23
DE68924928D1 (de) 1996-01-11

Similar Documents

Publication Publication Date Title
ATE130855T1 (de) Antikörper gegen latente proteine von menschlichen papillomavirus, diagnostische systeme und methoden.
ATE177754T1 (de) Fragmente von prion proteinen.
DE59010787D1 (de) Erythropoietin (EPO)-Peptide und dagegen gerichtete Antikörper
FI882173A7 (fi) Synteettinen peptidiantigeeni HIV-2-tartunnan toteamiseksi.
NO870412D0 (no) Peptider.
DK228190A (da) Rajgraespollenallergen
DE69130396D1 (de) Vergrössertes western blot format und ein immunotestverfahren für die bestimmung von viralen antikörpern
DE3584035D1 (de) Nachweis von menschlichem cytomegalovirus-spezifischem igm.
ATE51709T1 (de) Antigen im zusammenhang mit der fruehzeitigen feststellung von schwangerschaft bei saeugern.
BE857121A (fr) Antigene et anticorps pour un essai de determination immunologique de la thymopoietine, et leur application
ATE119203T1 (de) Monoklonale antikörper von mäusen gegen das gp41 protein von menschlichem immunmangelsyndrom- virus.
DE69008535D1 (de) Humane antigammainterferonantikörper, welche detektiert und geklärt sind mit verwendung von synthetischen peptiden.
PT625157E (pt) Epitopes p1a1 e p1a2 da gpiiia da plaqueta sua preparacao e utilizacao
DE69028561D1 (de) Immunoassay zum Nachweis von Antikörpern gegen HIV
DE3482924D1 (de) Reagenz zur verwendung im nachweis des antikoerpers gegen menschliche t-zellen-leukemievirusantigene.
IT8021411A0 (it) Polipeptide sintetico attivo come antigene, e procedimento per la sua preparazione.
ATE153770T1 (de) Künstliche standard- und kontrollseren zur verwendung in verfahren zur bestimmung von antikörpern
ATE60445T1 (de) Verfahren und testelement zum auffinden von zellaesionen.
DE69328488D1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
ATE134648T1 (de) Künstliche polypeptide und antikörper in zusammenhang mit epstein-barr-virus-nuklear- antigen
FI922710A0 (fi) Eliminering av aktiverade lymfocyter.
DE3886032D1 (de) Hiv-1-verwandte polypeptide, diagnosesysteme und testverfahren.
RU96119723A (ru) Способ выявления т-зависимого иммунодефицита
MX9707020A (es) Compuestos y metodos para la deteccion de infeccion por t. cruzi.
ATA179288A (de) Antikoerper gegen proteine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time